Performance-Enhancing Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The performance-enhancing drugs market is projected to expand from USD 483.62 million in 2025 and USD 513.23 million in 2026 to USD 733.58 million by 2031, registering a CAGR of 7.41% between 2026 and 2031. This report is segmented by Drug Type (Anabolic Steroids, Stimulants, and More), Route of Administration (Oral, Parenteral, and More), Dosage Form (Pills and Supplements, Injections, and More), Application (Athletic Performance, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Value (USD).

Global Performance-Enhancing Drugs Market Trends and Insights

Rising Demand for Performance Optimization in Competitive Sports and Fitness

The mainstream spread of testosterone replacement therapy is one of the clearest structural changes in the performance-enhancing drugs market. In July 2026, the US Department of Defense announced annual testosterone deficiency screening for all service members aged 30 and above, with optional access for younger personnel and treatment where deficiency is confirmed.That move shows that testosterone optimization is being treated more like a broader health protocol and less like a narrow edge-case intervention. In September 2025, Hims & Hers launched a dedicated men’s TRT category with exclusive access to KYZATREX, an FDA-approved oral testosterone product that restored testosterone levels in 96% of patients while avoiding injections. As telehealth lowers prescription friction, the performance-enhancing drugs market is seeing more clinical-grade anabolic steroid demand move through licensed channels instead of informal supply routes.

Expansion of Online and Cross-Border Supply Networks

Digital dispensing is becoming a stronger distribution backbone in the performance-enhancing drugs market, especially for products that are sold OTC or under lighter prescription controls. Redcare Pharmacy reported that its prescription drug revenue in Germany nearly doubled to EUR 503 million in 2025, while group Rx revenue rose 42.6% year over year to EUR 1.1 billion. These figures show how quickly consumers are shifting from physical pharmacies to digital channels in regulated settings. The same convenience also supports cross-border gray-market activity, which remains a major force in the performance-enhancing drugs market. INTERPOL said Operation Pangea XVII dismantled 123 criminal groups operating across 90 countries and shut down around 13,000 criminal-linked websites, social media pages, and channels that marketed illicit products. This combination shows that legal online pharmacies and illicit digital sellers are competing for the same demand base.

Stringent Anti-Doping Enforcement and Prescription Controls

Anti-doping enforcement is scaling up in ways that directly affect the performance-enhancing drugs market. The International Testing Agency said it collected more than 44,400 samples from over 17,200 athletes across 216 countries in 2024, which was a 10% increase from 2023, and it managed 532 potential rule violations, with 232 leading to sanctions. India also remained a major testing market, with 7,113 tests and 260 adverse analytical findings in 2024 before the positivity rate fell to 1.5% across 7,068 tests in 2025 after stronger education and monitoring efforts. The bigger commercial issue is that newer peptides and SARMs are being added or reclassified on prohibited lists, which narrows the gray area where many compounds have been marketed. That trend raises legal risk, limits open distribution, and forces the performance-enhancing drugs market to favor approved therapies over loosely positioned products.

Other drivers and restraints analyzed in the detailed report include:

• Better Targeting Through Long-Acting, Safer, and More Selective Formulations
• Rising Clinical Use in Hormonal and Muscle-Wasting Indications
• Counterfeit and Substandard Product Penetration

Segment Analysis

Anabolic steroids held 39.34% of the performance-enhancing drugs market share in 2025. Their lead reflected decades of established use in testosterone replacement therapy and muscle-wasting conditions. The category also benefited from a broad generic manufacturing base, which supported supply across both prescription and gray-market channels. In the performance-enhancing drugs industry, stimulants remained the second-largest segment, while beta-blockers and diuretics served narrower use cases linked to cognitive performance, weight control, and precision or weight-class sports.

The performance-enhancing drugs market for human growth hormone and peptides is projected to expand at a 9.55% CAGR through 2031. Once-weekly HGH products are widening legitimate clinical access, which strengthens the reference demand that supports this category. The July 2025 FDA approval of SKYTROFA for adults with growth hormone deficiency widened adult treatment access.

The oral route commanded a 38.52% share in 2025, which reflected enduring consumer preference for convenience. Oral formats fit both prescription and OTC demand in the performance-enhancing drugs market and remain easier to distribute across retail and digital settings. Topical and transdermal routes also remain relevant where users want needle-free administration and steady hormone delivery. These formats help preserve adherence in long-cycle therapy and broaden access for users who avoid injections.

The performance-enhancing drugs market for parenteral administration is projected to grow at an 8.17% CAGR through 2031. Injectable formats are gaining relevance because they offer precise dosing, strong bioavailability, and easier integration into medically supervised micro-dosing protocols. The performance-enhancing drugs market is also seeing more regulatory support for injectable testosterone formats, which strengthens the clinical role of parenteral use. In the United States, Schedule III controls create a barrier that keeps a large share of compliant injectable demand inside hospital and licensed retail pharmacy channels.

Complete Report Scope:

• By Drug Type
  • Anabolic Steroids
  • Stimulants
  • Human Growth Hormone and Peptides
  • Selective Androgen Receptor Modulators
  • Beta-Blockers
  • Diuretics
  • Other Drug Types
• By Route of Administration
  • Oral
  • Parenteral
  • Topical
  • Transdermal
  • Other Routes of Administration
• By Dosage Form
  • Pills and Supplements
  • Injections
  • Patches
  • Oral Liquids
  • Topical Creams
• By Application
  • Athletic Performance
  • Bodybuilding and Muscle Enhancement
  • Cognitive Enhancement
  • Anti-Aging and Wellness
  • Weight Loss and Management
  • Other Applications
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 46.23% of the performance-enhancing drugs market share in 2025. The region leads because the United States has an established testosterone replacement therapy base, a large number of licensed dispensing channels, and stronger telehealth participation. The July 2026 Department of Defense screening initiative adds another layer of institutional demand by treating testosterone deficiency as a broader health issue. Canada is also gaining importance in the performance-enhancing drugs market, and Hikma’s May 2026 licensing agreement for KYZATREX shows that multinational companies view it as a structured extension of the North American therapy base.

Europe remained the second-largest regional footprint in the performance-enhancing drugs market. The region combines deep prescription infrastructure with stronger cross-border oversight, which makes it both commercially attractive and operationally demanding. OLAF’s SHIELD V operation in January 2025 seized more than 3.4 million pills, including anabolic steroids and doping substances, across EU member states. France’s 2026 Inserm review also pointed to rising anabolic steroid use among gym populations, which suggests that non-elite demand remains active even under tighter surveillance.

Asia-Pacific is projected to grow fastest at a 10.13% CAGR through 2031, making it the performance-enhancing drugs market size leader in growth terms. The region benefits from rising disposable income, stronger supplement acceptance, and a younger consumer base that is heavily influenced by social media and appearance-led fitness behavior. India shows both the demand side and the enforcement side of the performance-enhancing drugs market, with 260 adverse analytical findings from 7,113 tests in 2024, before the positivity rate fell sharply in 2025. Japan and South Korea remain more compliance-led markets, while parts of Southeast Asia are emerging as broader volume channels. In the Middle East and Africa, wealthy GCC consumers and South Africa’s sports base support demand, while Brazil remains the key South American market because bodybuilding culture and local pharmaceutical capacity continue to support the wider performance-enhancing drugs market.

List of Companies Covered in this Report:

• Abbvie
• Aurobindo Pharma
• Balkan Pharmaceuticals
• Bayer
• Cipla
• Dr. Reddy’s Laboratories
• Eli Lilly and Company
• Hikma Pharmaceuticals
• Lupin
• Mankind Pharma Ltd.
• Merck
• Novartis
• Novo Nordisk
• Nutrabolt
• Pfizer
• Roche
• Sanofi
• Sun Pharmaceuticals Industries
• Taj Pharmaceuticals
• Teva Pharmaceutical Industries
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support